US 11,629,192 B2 · Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway

Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway

AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Université Paris Cité, Fondation Imagine, Assistance Publique-HôPitaux De Paris (Aphp), Centre National de la Recherche Scientifique (CNRS), Universite Grenoble Alpes, Commissariat A L'energie Atomique Et Aux Energies Alternatives, Universite De Bourgogne

InventorsZakia Belaid-Choucair, Olivier Hermine, Carmen Garrido-Fleury, Claude Cochet, Odile Filhol-Cochet, Renaud Seigneuric

Life of this patent

Estimating the term…

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

Claims4

Dependent claims

A method for treating a cancer having cells that express neuropilin-1 (NRP-1)/OBR complex in a subject in need thereof comprising

determining that the cancer has cells expressing the NRP-1/OBR complex;
and
administering to the subject a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway, wherein the antagonist of the NRP-1/OBR signaling pathway is a CK2 inhibitor such that the CK2 inhibitor inhibits transport of the NRP-1/OBR complex to the nucleus of the cells expressing the NRP-1/OBR complex.

Dependencies are inferred from the claim text.

Facts

Application

16/120,514Filed 4 Sep 2018 · division

Priority

EP 1430522018 Feb 2014

Published

US 2019/0002569 A13 Jan 2019

Granted

18 Apr 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification31 codes

C07K 16/2863
Against receptors, cell surface antigens or cell surface determinants: against receptors for growth factors, growth regulators
A61K 31/4745
Ortho- or peri-condensed with heterocyclic ring systems: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
A61K 31/7105
Compounds having three or more nucleosides or nucleotides: natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine,…
A61K 31/713
Compounds having three or more nucleosides or nucleotides: double-stranded nucleic acids or oligonucleotides

Family

PCT/EP2015/053355Parent of this division · filed 18 Feb 2015

US 2019/0002569 A1Pre-grant publication · published 3 Jan 2019

Application15/119,401Parent of this division

US 2017/0051062 A1Published application

US 11,629,192 B2This patent

From the US filing history. Foreign family members aren’t listed.